Refine
Has Fulltext
- yes (12)
Is part of the Bibliography
- yes (12)
Document Type
- Journal article (12)
Language
- English (12)
Keywords
- Parkinson's disease (2)
- neurology (2)
- neuropathy (2)
- skin punch biopsy (2)
- Antiparanodal Autoantibodies (1)
- CIDP (1)
- Charcot–Marie–Tooth disease type 1A (1)
- Diabetes mellitus (1)
- Guillain-Barre-Syndrome (1)
- IENFD (1)
- Langerhans cells (1)
- MIBG scintigraphy (1)
- Merkel cell density (1)
- Nodo-parandopathy (1)
- anti-contactin-1 (1)
- antibodies (1)
- autoantibodies (1)
- autoantibody (1)
- barrier (1)
- behavioral disorders (1)
- binding (1)
- binding analysis (1)
- biopsies (1)
- cell binding assay (1)
- chronic constriction nerve injury (1)
- complement deposition (1)
- complex regional pain syndrome (1)
- dermal B cells (1)
- diagnostic markers (1)
- enzyme assays (1)
- enzyme-linked immunoassays (1)
- glycine receptor autoantibodies (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- inflammatory neuropathy (1)
- intraepidermal nerve fibre density (1)
- macrophages (1)
- mast cells (1)
- motor proteins (1)
- multiple system atrophy (1)
- musk myasthenia gravis (1)
- nerve biopsy (1)
- nerve fibers (1)
- nerve tumor (1)
- neurofascin (1)
- neuroleukemiosis (1)
- nociceptive Schwann cells (1)
- ontactin 1 (1)
- pain (1)
- paranodopathy (1)
- passive transfer (1)
- periperal nerve (1)
- peripheral nervous system (1)
- reproducible outcome measure (1)
- skin biopsy (1)
- switch (1)
- tissue resident T cells (1)
Objective
To determine whether IgG subclasses of antiparanodal autoantibodies are related to disease course and treatment response in acute- to subacute-onset neuropathies, we retrospectively screened 161 baseline serum/CSF samples and 66 follow-up serum/CSF samples.
Methods
We used ELISA and immunofluorescence assays to detect antiparanodal IgG and their subclasses and titers in serum/CSF of patients with Guillain-Barre syndrome (GBS), recurrent GBS (R-GBS), Miller-Fisher syndrome, and acute- to subacute-onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP). We evaluated clinical data retrospectively.
Results
We detected antiparanodal autoantibodies with a prevalence of 4.3% (7/161), more often in A-CIDP (4/23, 17.4%) compared with GBS (3/114, 2.6%). Longitudinal subclass analysis in the patients with GBS revealed IgG2/3 autoantibodies against Caspr-1 and against anti-contactin-1/Caspr-1, which disappeared at remission. At disease onset, patients with A-CIDP had IgG2/3 anti-Caspr-1 and anti-contactin-1/Caspr-1 or IgG4 anti-contactin-1 antibodies, IgG3 being associated with good response to IV immunoglobulins (IVIg). In the chronic phase of disease, IgG subclass of one patient with A-CIDP switched from IgG3 to IgG4.
Conclusion
Our data (1) confirm and extend previous observations that antiparanodal IgG2/3 but not IgG4 antibodies can occur in acute-onset neuropathies manifesting as monophasic GBS, (2) suggest association of IgG3 to a favorable response to IVIg, and (3) lend support to the hypothesis that in some patients, an IgG subclass switch from IgG3 to IgG4 may be the correlate of a secondary progressive or relapsing course following a GBS-like onset.